Laval, Quebec – April 13^th, 2008 – Dr Andrew Vaillant, Chief Scientific Officer, presented the company latest developments at the 21st International Conference on Antiviral Research held at Le Centre Sheraton Hotel, Montreal on April 13-17, 2008. The presentation titled “Preclinical development of the amphipathic DNA polymer REP 9AC for the treatment of hepatitis B virus infection” is resulting from a long term collaboration with Dr Allison Jilbert from The University of Adelaide, Australia.